A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Inclusion Criteria:

Diagnosis of plaque psoriasis (PsO) for ≥ 6 months
Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs)
Deemed by Investigator to be eligible for phototherapy or systemic therapy
Psoriatic plaques must cover ≥ 10% of body surface area at baseline
Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline

Exclusion Criteria:

Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic)
Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
Any significant acute or chronic medical illness

Other protocol-defined inclusion/exclusion criteria apply